More Detail About Mevacor Interactions
Cyclosporine (Gengraf, Neoral, Sandimmune)
Taking both cyclosporine and
Mevacor together may cause your body to metabolize the medicines differently than intended. This can cause significant reactions, including increasing the risk for developing serious muscle problems, such as myopathy or rhabdomyolysis. Your healthcare provider may choose to monitor your progress closely and make necessary dosing adjustments. Your
Mevacor dosage should not exceed 20 mg.
Danazol (Danocrine)
Taking danazol and Mevacor together may cause your body to metabolize the medicines differently than intended. This can cause significant reactions, including increasing the risk for developing serious muscle problems, such as myopathy or rhabdomyolysis. Your healthcare provider may choose to monitor your progress closely and make necessary dosing adjustments. Your dosage of Mevacor should not exceed 20 mg.
Warfarin (Coumadin, Jantoven)
If you are taking both Mevacor and warfarin, your body may metabolize the medicines differently than intended. When starting Mevacor therapy or changing the Mevacor dosage, your healthcare provider may choose to monitor your INR more closely and make any necessary adjustments. An INR is a test that measures how long it takes for your blood to clot.
Gemfibrozil (Lopid)
If you are taking Mevacor with
gemfibrozil, your body may metabolize the medicines differently than intended. This can cause significant reactions, including increasing the risk for developing serious muscle problems, such as myopathy or rhabdomyolysis. To decrease this risk, your dosage of Mevacor should not exceed 20 mg per day.
Other Fibrates (Tricor, Antara, Lipofen, Triglide, Lofibra)
If you are taking Mevacor with fibrates, your body may metabolize both drugs differently than intended. This can cause significant reactions, including increasing the risk for developing serious muscle problems, such as myopathy or rhabdomyolysis. To decrease this risk, your dosage of Mevacor should not exceed 20 mg daily.
Previous
Add this article to your Favorites
Email this article
Print